Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression

Huang, Wei-ChiehWei-ChiehHuangHuang, Chun-KaiChun-KaiHuangHuang, Sung-HsiSung-HsiHuangSHU-WEN LINOu, Shyh-TyanShyh-TyanOuChen, Yi-TingYi-TingChenChen, Ya-WenYa-WenChenChang, Shu-YuanShu-YuanChangLiu, Wen-ChunWen-ChunLiuHSIN-YUN SUNCHIEN-CHING HUNG2022-05-052022-05-052021-1016841182https://scholars.lib.ntu.edu.tw/handle/123456789/609470This study evaluated the efavirenz (EFV) mid-dose plasma concentration (C12), clinical efficacy, and safety after the switch to a single-tablet regimen containing tenofovir disoproxil fumarate (TDF), lamivudine (3TC), and 400-mg EFV in virally suppressed HIV-positive Taiwanese who were receiving co-formulated TDF, emtricitabine (FTC), and 600-mg EFV.enAntiretroviral therapy; Mid-dose plasma concentration; Neuropsychiatric adverse effects; Non-nucleoside reverse transcriptase inhibitor; Switch therapy[SDGs]SDG3Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppressionjournal article10.1016/j.jmii.2020.06.010326750422-s2.0-85087959347https://scholars.lib.ntu.edu.tw/handle/123456789/588692